Analysis of the Reasons for Non-Uptake of Predictive Testing for Huntington’s Disease in Spain: A Qualitative Study

Journal of Genetic Counseling

Volumn 24, Issue 6, 2015, Pages 1011-1021

  Rivera Navarro, Jesús ^a   Cubo, Esther ^b   Mariscal, Natividad ^b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b HOSPITAL UNIVERSITARIO DE BURGOS   (Spain)

Author keywords

Explanatory factors; Genetic testing; Huntington s disease; Qualitative method

Indexed keywords

ADULT; ATTITUDE TO HEALTH; CHILD; EPIDEMIOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETIC SCREENING; GENETICS; HUMAN; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PERSONALITY; PSYCHOLOGY; QUALITATIVE RESEARCH; SPAIN; STATISTICS AND NUMERICAL DATA;

ADULT; ATTITUDE TO HEALTH; CHILD OF IMPAIRED PARENTS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; HUNTINGTON DISEASE; MALE; MIDDLE AGED; PERSONALITY; QUALITATIVE RESEARCH; SPAIN;

EID: 84947027806     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-015-9840-x     Document Type: Article

References (81)

1. Alper, J. S., Ard, C., Asch, A., Beckwith, J., Conrad, P., & Geller, L. (Eds.). (2002). The doubled-edged helix: Social implications of genetics in a diverse society. Baltimore: Johns Hopkins University Press.
2. Babul, R., Adams, S., Kremer, B., Dufrasne, S., Wigginns, S., Huggins, M., Theilmann, J., Bloch, M., & Hayden, M. R. (1993). Attitudes toward direct predictive testing for the Huntington disease gene. Relevance for other adult-onset disorders. The Canadian collaborative group on predictive testing for Huntington Disease. JAMA, 270, 2321–2325.
3. Bernhardt, C., Schwan, A. M., Kraus, P., Epplen, J. T., & Kunstmann, E. (2009). Decreasing uptake of predictive testing for Huntington’s disease in a German centre: 12 years’ experience (1993–2004). European Journal of Human Genetics, 17, 295–300.
4. Binedell, J., Soldan, J. R., & Harper, P. S. (1998a). Predictive testing for Huntignton’s disease: I. Predictors of uptake in South Wales. Clinical Genetics, 54, 477–488.
5. Binedell, J., Soldan, J. R., & Harper, P. S. (1998b). Predictive testing for Huntignton’s disease: II. Qualitative findings from a study of uptake in South Wales. Clinical Genetics, 54, 489–496.
6. Bloch, M., Adam, S., Wiggins, S., Huggins, M., & Hayden, M. R. (1992). Predictive testing for Huntington disease in Canada: the experience of those receiving an increased risk. American Journal of Medical Genetics, 42, 499–507.
7. Bombard, Y., Veenstra, G., Friedman, J.M., Creighton, S., Currie, L., Paulsen, J.S., Bottordd, J.L., Hayden, M.R., & Canadian Respond-HD Collaborative Research Group. (2009). British Medical Journal, 9, 338:b2175. Doi: 10.1136/bmj.b2175
8. Burguera, J. A., Solis, P., & Salazar, A. (1997). Estimate of the prevalence of Huntington disease in the Valencia region using the capture-recapture method. Revista de Neurologia, 25, 1845–1847.
9. Chapman, E. (2002). Ethical dilemmas in testing for late onset conditions: reactions to testing and perceived impact on other family members. Journal of Genetic Counseling, 11, 351–367.
10. Chen, L. S., Zhao, M., Zhou, Q., & Xu, L. (2012). Chinese Americans’ views of prenatal genetic testing in the genomic era: a qualitative study. Clinical Genetics, 82, 22–27.
11. Chisholm, L. Z., Flavin, K. T., Paulsen, J. S., & Ready, R. (2013). Psychological well-being in persons affected by Huntington’s disease: a comparison of at-risk prodromal and symptomatic groups. Journal of Health Psychology, 18, 408–418.
12. Codori, A.-M., & Brandt, J. (1994). Psychological costs and benefits of predictive testing for Huntington’s disease. American Journal of Medical Genetics, 54, 174–184.
13. Cooke, L. P. (2009). Gender equity and fertility in Italy and Spain. Journal of Social Policy, 38, 123–140.
14. Coulson, N. S., Buchanan, H., & Aubeeluck, A. (2007). Social support in cyberspace: a content analysis of communication within a Huntington’s disease online support group. Patient Education and Counselling, 68, 173–178.
15. Cox, S. M. (Ed.). (1999). Personal perspectives on genetic testing for Huntington’s disease: A collection of stories. Ontario: The Huntington Society of Canada.
16. Cox, S. M., & McKelling, W. (1999). There’s this thing in our family’: predictive testing and the construction of risk for Huntington’s disease. Sociology of Health and Illness, 21, 622–646.
17. Craufurd, D., Kerzin-Storrar, L., Dodge, A., & Harris, R. (1989). Uptake of presymptomatic predictive testing for Huntington’s disease. Lancet, 2, 603–605.
18. Creighton, S., Almqvist, E. W., MacGregor, D., Fernández, B., Hogg, H., Beis, J., Welch, J. P., Riddell, C., Lokkesmoe, R., Khalifa, M., Mackenzie, J., Sajoo, A., Farrell, S., Robert, F., Shugar, A., Summers, A., Meschino, W., Allingham-Hawkins, D., Chiu, T., Hunter, A., Allanson, J., Hare, H., Schween, J., Collins, L., Sanders, S., Greenberg, C., Cardwell, S., Lemire, E., MacLeod, P., & Hayden, M. R. (2003). Predictive, prenatal and diagnostic genetic testing for Huntington’s disease: the experience in Canada from 1987 to 2000. Clinical Genetics, 63, 462–475.
19. Decruyenaere, M., Evers-Kiebooms, G., & van den Berghe, H. (1993). Perception of predictive testing for Huntintong’s disease by young women: preferring uncertainty to certainty? Journal of Medical Genetics, 30, 557–561.
20. Decruyenaere, M., Evers-Kiebooms, G., Boogaerts, A., Cassiman, J., Cloostermans, T., Demyttenaere, K., Dom, R., Fryns, J. P., & van den Berghe, H. (1995). Predictive testing for Huntington’s disease: risk perception, reasons for testing and psychological profile of test applicants. Genetic Counselling, 6, 1–13.
21. Decruyenaere, M., Evers-Kiebooms, G., Cloostermans, T., Boogaerts, A., Demyttenaere, K., Dom, R., & Fryns, J. P. (2003). Psychological distress in the 5-year period after predictive testing for Huntington’s disease. European Journal of Human Genetics, 11, 30–38.
22. Decruyenaere, M., Evers-Kiebooms, G., Boogaerts, A., Phillippe, K., Demyttenaere, K., Dom, R., Vandenberghe, W., & Fryns, J. P. (2007). The complexity of reproductive decision-making in asymptomatic carriers of the Huntington mutation. European Journal of Human Genetics, 15, 453–462.
23. Del Pino-Casado, R., Frías-Osuna, A., & Palomino-Moral, P. A. (2011). Subjective burden and cultural motives for caregiving in informal caregivers of older people. Journal of Nursing Scholarship, 43, 282–291.
24. DiMaio, L., Squitieri, F., Napolitano, G., Campanella, G., Trofatter, J. A., & Conneally, P. M. (1993). Onset symptoms in 510 patients with Huntington’s disease. Journal of Medical Genetics, 30, 289–292.
25. Duncan, R. E., Gillam, L., Savulescu, J., Williamson, R., Rogers, J. G., & Delatycki, M. B. (2008). “You’re one of us now”: young people describe their experiences of predictive genetic testing for Huntington Disease (HD) and Familial Adenomatous Polyposis (FAP). American Journal of Medcial Genetics. Part C, Seminars in Medical Genetics, 148C, 47–55.
26. Erwin, C., Williams, J. K., Juhl, A. R., Mengeling, M., Mills, J. A., Bombard, Y., Hayden, M. R., Quaid, K., Shoulson, I., Taylor, S., Paulsen, J. S., & I-Respond-Hd Investigators of the Huntington Study Group. (2010). Perception, experience, and response to genetic discrimination in Huntington disease: the international RESPOND-HD study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 153, 1081–1093.
27. Evers-Kiebooms, G., Weilkenhuysen, M., Claes, E., Decruyenaere, M., & Denayer, L. (2000). The psychological complexity of predictive testing for late onset neurogenetic diseases and hereditary cancers: implications for multidisciplinary counselling and for genetic education. Social Science and Medicine, 51, 831–841.
28. Goh, A. M., Chiu, E., Yastrubetskaya, O., Erwin, C., Williams, J. K., Juhl, A. R., Paulsen, J. S., & I-Respond-Hd Investigators of the Huntington Study Group. (2013). Genetic Testing and Molecular Biomakers, 17, 115–121.
29. Goizet, C., Lesca, G., & Durr, A. (2002). Presymptomatic testing in Huntington’s disease and autosomal dominant cerebellar ataxias. Neurology, 59, 1330–1336.
30. Ha, A. D., & Fung, V. S. (2012). Huntington’s disease. Current Opinion in Neurology, 25, 491–498.
31. Harper, P. S. (1992). The epidemiology of Huntington’s disease. Human Genetics, 89, 365–376.
32. Hoppit, T., Pall, H., Calvert, M., Gill, P., Yao, G., Ramsay, J., James, G., Conduit, J., & Sackley, C. (2011). A systematic review of the incidence and prevalence of long-term neurological conditions in the UK. Neuroepidemiology, 36, 19–28.
33. Hsieh, H.-F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15, 1277–1288.
34. Huggins, M., Bloch, M., Wiggins, S., Adam, S., Suchowersky, O., Trew, M., Klimek, M., Greenberg, C. R., Eleff, M., Thompson, L. P., Knight, J., MacLeod, P., Girard, K., Theilmann, J., Hedrick, A., & Hayden, M. R. (1992). Predictive testing for Huntington disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. American Journal of Medical Genetics, 42, 508–515.
35. Jurado, T. G., & Naldini, M. (1996). Is the South so different? Italian and Spanish families in comparative perspective. South European Society and Politics, 1, 42–66.
36. Kessler, S., Field, T., Worth, L., Mosbarger, H., Opitz, J. M., & Reynolds, J. F. (1987). Attitudes of persons at risk for Huntington disease toward predictive testing. American Journal of Medical Genetics, 26, 259–270.
37. Licklederer, C., Wolff, G., & Barth, J. (2008). Mental health and quality of life after genetic testing for Huntington disease: a long-term effect study in Germany. American Journal of Medical Genetics Part A, 146A, 2078–2085.
38. Loi, S., & Chiu, E. (2012). Witchcraft and Huntington’s disease: a salutary history of societal and medical stigmatization. Australasian Psychiatry, 20, 438–441.
39. Losada, A., Knight, B. G., & Márquez, M. (2003). Cognitive barriers against caregiving to elderly dependent individuals. The influence of sociocultural variables. Revista Española de Geriatría y Gerontología, 38, 116–123.
40. Maat-Kievit, A., Vegter-van der Vlis, M., Zoeteweij, M., Losekoot, M., van Haeringen, A., & Roos, R. (2000). Paradox of a better test for Huntington’s disease. Journal of Neurology, Neurosurgery and Psychiatry, 69, 579–583.
41. Mattsson, B., & Almqvist, E. W. (1991). Attitudes towards predictive testing in Huntington’s disease- a deep interview study in Sweden. Family Practice, 8, 23–27.
42. Maya Jariego, I. (2009). Sentido de la comunidad y potenciación comunitaria. Miriada, 3, 69–109.
43. Meil, G. L. (2000). Cambio familiar y solidaridad familiar en España. Revista del Ministerio de Trabajo y Asuntos Sociales, 26, 129–154.
44. Meiseen, G., Berchek, R., Opitz, J. M., & Reynolds, J. F. (1987). Intented use of predictive testing by those at risk for Huntington disease. American Journal of Medical Genetics, 26, 283–293.
45. Morgan, D. L. (1998). Planning focus groups. London: Sage Publications.
46. Morrison, P. J. (2010). Accurate prevalence and uptake of testing for Huntington’s disease. The Lancet Neurology, 9, 1147.
47. Morse, J. M., & Field, P. A. (1995). Qualitative research methods health professionals. Thousand Oaks: Sage Publications.
48. Nagaraja, S. M., Jain, S., & Muthane, U. B. (2006). Perspectives towards predictive testing in Huntington disease. Neurology India, 54, 359–362.
49. Otlowski, M. F., Taylor, S. D., & Barlow-Stewart, K. (2002). Major study commencing into genetic discrimination in Australia. Journal of Law and Medicine, 10, 41–48.
50. Panegyres, P. K., & Goh, J. G. (2011). The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene. Journal of the Neurological Sciences, 301, 14–20.
51. Paneque, M., Sequeiros, J., & Skirton, H. (2012). Quality assessment of genetic counselling process in the context of presymptomatic testing for late-onset disorders: a thematic analysis of three review articles. Genetic Testing and Molecular Biomarkers, 16, 36–45.
52. Penziner, E., Williams, J. K., Erwin, C., Bombard, Y., Wallis, A., Beglinger, L. J., Hayden, M. R., & Paulsen, J. S. (2008). American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 147, 320–325.
53. Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T., & Jette, N. (2012). The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Movement Disorders, 27, 1083–1091.
54. Quine, S. (1999). Focus groups. In C. B. Kerr, J. R. Taylor, & G. S. Heard (Eds.), Handbook of public health methods. Sydney: McGraw-Hill/Spanish imports (Thirdth ed., pp. 527–532). London: Sage Publications.
55. Ramos-Arroyo, M. A. (1998). El consejo genético en neurología: aspectos prácticos y éticos. Neurología, 13, 126–131.
56. Richards, F. H. (2006). Maturity of judgment in decision making for predictive testing for nontreatable adult-onset neurogenetic conditions: a case against predictive testing of minors. Clinical Genetics, 70, 396–401.
57. Richartz-Salzburger, E., Mau-Holzmann, U., Schott, K. J., & Buchkrmer, G. (2006). Predictive diagnostics in chorea huntington: pscychoterapeutic implications for counselling. Psychiatrische Praxis, 33, 211–217.
58. Rivera-Navarro, J., Cubo, E., & Almazán, J. (2009). The diagnosis of Tourette’s syndrome: communication and impact. Clinical Child Psychology and Psychiatry, 14, 13–23.
59. Rivera-Navarro, J., Cubo, E., & Almazán, J. (2014). The impact of Tourette’s syndrome in the school and the family: perspectives from three stakeholder groups. International Journal for the Advancement of Counselling, 36, 96–113.
60. Ros, M., & Schwartz, S. (1995). Jerarquía de valores en países de la Europa Occidental. Una comparación transcultural. Revista Española de Investigaciones Sociológicas, 69, 69–98.
61. Ruíz, J. F. (2004). Tests genéticos: Implicaciones éticas y jurídicas. In Fundación española para el desarrollo de la investigación en Genómica y Proteómica (Ed.), Genoma y medicicina (pp. 129–147). Madrid: Genoma España.
62. Sandelowski, M. (2000). Focus on research methods. Whatever happened to qualitative description? Research in Nursing & Health, 23, 334–340.
63. Sarangi, S., Bennert, K., Howell, L., Clarke, A., Harper, P., & Gray, J. (2005). (Mis) alignments in counseling for Huntington’s Disease predictive testing: clients’ responses to reflective frames. Journal of Genetic Counselling, 14, 29–42.
64. Sarasola, E. D., & García, M. B. (2014). Impacto psicosocial del diagnóstico y consejo genético en enfermedades neuromusculares. In I. C. Amayra, J. F. López-Paz, & E. P. Lázaro (Eds.), Enfermedades neuromusculares. Bases para la intervención (pp. 167–176). Bilbao: Universidad de Deusto.
65. Sermeus, W. (2012). Impact of the financial crisis and health workforce crisis on the sustainability of the healthcare system: what’s next? Enfermería Clínica, 22, 179–181.
66. Shulman, J. D., & Stern, H. D. (2014). Low utilization of prenatal and pre-implantation genetic diagnosis in Huntington disease-risk discounting in preventive genetics. Clinical Genetics. doi:10.1111/cge.12523 [not yet printed on paper].
67. Sizer, E. B., Haw, T., Wessels, T. M., Kromberg, J. G., & Krause, A. (2012). The utilization and outocome of diagnostic and outcome of diagnostic, predictive, and prenatal genetic testing for huntington disease in Johannesgrug, South Africa. Genetic Testing and Molecular Biomarkers, 16, 58–62.
68. Sobel, S. K., & Cowan, D. B. (2000). Impact of genetic testing for Huntington disease on the family system. American Journal of Medical Genetics, 90, 49–59.
69. Taylor, S. D. (2005). Predictive genetic test decisions for Huntington’s disease: elucidating the test/no-test dichotomy. Journal of Health Psychology, 10, 597–612.
70. Taylor, C. A., & Myers, R. H. (1997). Long-term impact of Huntington disease linkage testing. American Journal of Medical Genetics, 70, 365–370.
71. Tibben, A. (2007). Predicitive testing for Huntington’s disease. Brain Research Bulletin, 72, 165–171.
72. Tibben, A., Duivenvoorden, H. J., Vegter-van der Vils, M., Niermeijer, M., Fres, P. G., van de Kamp, J. J., Roos, R., Rooijmans, H. G., & Verhage, F. (1993). Presymptomatic DNA testing for Huntington disease: identifying the need for psychological intervention. American Journal of Medical Genetics (Neuropsychiatric Genetics), 48, 137–144.
73. Timman, R., Roos, R., Maat-Kievit, A., & Tibben, A. (2004). Adverse effects of predictive testing for Huntington disease underestimated: long-term effects 7–10 years after the test. Health Pscychology, 23, 189–197.
74. Timman, R., Claus, H., Slingerland, H., van der Schalk, M., Demeulenaere, S., Roos, R. A., & Tibben, A. (2005). Nature and development of Huntington disease in a nursing home popularion: the Behavior Observation Scale Huntington (BOSH). Cognitive and Behavioral Neurology, 18, 215–222.
75. Uhrová, T., Zidovska, J., Koblihová, J., Klempír, J., Majerová, V., & Roth, J. (2013). Importance of psychiatric examination in predictive genetic testing for Huntington disease. Neurologia I Neurochirurgia Polska, 47, 534–541.
76. Van der Steenstraten, I. M., Tibben, A., Roos, R. A., Van de Kamp, J. J., & Niermeijer, M. F. (1994). Predictive testing for Huntington disease: nonparticipants compared with participants in the Dutch program. American Journal of Human Genetics, 55, 618–625.
77. Wahlin, T. B., Lundin, A., Backman, L., Almqvist, E., Haegermark, A., Winblad, B., & Anvret, M. (1997). Reactions to predictive testing in Huntington Disease: case reports of coping with a new genetic status. American Journal of Medical Genetics, 73, 356–365.
78. Walker, F. O. (2007). Huntington’s disease. Seminars in Neurology, 27, 143–150.
79. Williams, J. K., Erwin, C., Andrew, R. J., Mengeling, M., Bombard, Y., Hayden, M. R., Quaid, K., Shoulson, I., Taylor, S., Paulsen, J. S., & I-Respond-Hd Investigators of the Huntington Study Group. (2010a). In their own words: reports of stigma and genetic discrimination by people at risk for Huntington disease in the International RESPOND-HD Study. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 153, 1150–1159.
80. Williams, J. K., Erwin, C., Juhl, A., Mills, J., Brossman, B., Paulsen, J. S., & I-Respond-HD Investigators of the Huntington Study Group. (2010b). Personal factors associated with reported benefits of Huntington disease family history or genetic testing. Genetic Testing and Molecular Biomakers, 14, 629–636.
81. Wolff, G., & Walter, W. (1992). Attitudes of at-risk persons for Huntington disease toward predictive genetic testing. Birth Defects Original Article Series, 28, 119–126.